S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.37 (+1.02%)
AAPL   179.33 (+0.85%)
MSFT   326.41 (+0.94%)
META   266.90 (+1.25%)
GOOGL   122.88 (+0.31%)
AMZN   125.60 (+3.60%)
TSLA   232.62 (+3.58%)
NVDA   384.19 (+2.52%)
NIO   7.68 (-1.03%)
BABA   86.92 (+1.92%)
AMD   121.00 (+2.69%)
T   15.93 (-1.06%)
F   13.51 (-0.59%)
MU   65.03 (-3.03%)
CGC   0.71 (-2.34%)
GE   106.75 (+0.63%)
DIS   92.08 (-0.48%)
AMC   4.62 (-2.33%)
PFE   39.05 (+0.41%)
PYPL   64.59 (+0.86%)
NFLX   405.73 (+1.49%)
S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.37 (+1.02%)
AAPL   179.33 (+0.85%)
MSFT   326.41 (+0.94%)
META   266.90 (+1.25%)
GOOGL   122.88 (+0.31%)
AMZN   125.60 (+3.60%)
TSLA   232.62 (+3.58%)
NVDA   384.19 (+2.52%)
NIO   7.68 (-1.03%)
BABA   86.92 (+1.92%)
AMD   121.00 (+2.69%)
T   15.93 (-1.06%)
F   13.51 (-0.59%)
MU   65.03 (-3.03%)
CGC   0.71 (-2.34%)
GE   106.75 (+0.63%)
DIS   92.08 (-0.48%)
AMC   4.62 (-2.33%)
PFE   39.05 (+0.41%)
PYPL   64.59 (+0.86%)
NFLX   405.73 (+1.49%)
S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.37 (+1.02%)
AAPL   179.33 (+0.85%)
MSFT   326.41 (+0.94%)
META   266.90 (+1.25%)
GOOGL   122.88 (+0.31%)
AMZN   125.60 (+3.60%)
TSLA   232.62 (+3.58%)
NVDA   384.19 (+2.52%)
NIO   7.68 (-1.03%)
BABA   86.92 (+1.92%)
AMD   121.00 (+2.69%)
T   15.93 (-1.06%)
F   13.51 (-0.59%)
MU   65.03 (-3.03%)
CGC   0.71 (-2.34%)
GE   106.75 (+0.63%)
DIS   92.08 (-0.48%)
AMC   4.62 (-2.33%)
PFE   39.05 (+0.41%)
PYPL   64.59 (+0.86%)
NFLX   405.73 (+1.49%)
S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.37 (+1.02%)
AAPL   179.33 (+0.85%)
MSFT   326.41 (+0.94%)
META   266.90 (+1.25%)
GOOGL   122.88 (+0.31%)
AMZN   125.60 (+3.60%)
TSLA   232.62 (+3.58%)
NVDA   384.19 (+2.52%)
NIO   7.68 (-1.03%)
BABA   86.92 (+1.92%)
AMD   121.00 (+2.69%)
T   15.93 (-1.06%)
F   13.51 (-0.59%)
MU   65.03 (-3.03%)
CGC   0.71 (-2.34%)
GE   106.75 (+0.63%)
DIS   92.08 (-0.48%)
AMC   4.62 (-2.33%)
PFE   39.05 (+0.41%)
PYPL   64.59 (+0.86%)
NFLX   405.73 (+1.49%)
NASDAQ:CGIX

Cancer Genetics (CGIX) Stock Forecast, Price & News

$0.20
-0.01 (-4.68%)
(As of 06/7/2023 ET)
Compare
Today's Range
$0.20
▼
$0.23
50-Day Range
$0.20
▼
$0.60
52-Week Range
$2.11
▼
$17.50
Volume
29,835 shs
Average Volume
2.44 million shs
Market Capitalization
$831,297.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsHeadlinesSocial Media

CGIX stock logo

About Cancer Genetics (NASDAQ:CGIX) Stock

Vyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities. It leveraging these modalities, the company is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. It operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Vyant Bio was founded in 1999 and is headquartered in Cherry Hill, NJ.

Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

CGIX Stock News Headlines

June 7, 2023 | msn.com
KHCC presents Cancer Genetics study in leading conference in US
June 6, 2023 | msn.com
DNA sequencing can lead to longer, better lives for cancer patients. But why do so few get it?
June 8, 2023 | Edge On The Street (Ad)
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
June 3, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Cancer Genetics (NASDAQ:CGIX)
June 2, 2023 | msn.com
Endometrial Cancer Warning Signs: What to Look Out For
May 25, 2023 | msn.com
UCLA researchers say genetic mutation could be key to treating fatal brain tumors
May 25, 2023 | americanbankingnews.com
Cancer Genetics (NASDAQ:CGIX) Now Covered by Analysts at StockNews.com
May 18, 2023 | msn.com
Junk genes may hold keys to cancer cure, CWRU researchers find
June 8, 2023 | Edge On The Street (Ad)
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
May 17, 2023 | americanbankingnews.com
Cancer Genetics (NASDAQ:CGIX) Receives New Coverage from Analysts at StockNews.com
May 16, 2023 | technews.tmcnet.com
New Study Shows CancerIQ Plus Point-of-Care Genetic Testing Improves Access to Precision Prevention
May 9, 2023 | americanbankingnews.com
Cancer Genetics (NASDAQ:CGIX) Coverage Initiated by Analysts at StockNews.com
May 8, 2023 | washingtonpost.com
Ask a Doctor: Which cancers can be detected through genetic testing?
May 8, 2023 | markets.businessinsider.com
Genome Insight Launches in the U.S. with Innovative Whole Genome Sequencing Approach that Offers Unprecedented, Actionable Insights in Cancer Care
April 27, 2023 | msn.com
Calls for ban on insurance companies using genetic testing information as doctors warn it puts Kiwis at risk
April 12, 2023 | msn.com
Scientists say 'genetic clues' could lead to blood test tracking cancer growth in real time
April 3, 2023 | foxnews.com
AI testing of brain tumors can detect genetic cancer markers in less than 90 seconds, study finds
March 31, 2023 | msn.com
Canadian researchers find new gene mutation that could be linked to increased breast cancer risk
March 30, 2023 | dailymail.co.uk
Cancer
March 29, 2023 | foxnews.com
New breast cancer gene can predict likelihood of hereditary disease, study finds
March 27, 2023 | nypost.com
‘Holy grail’ of cancer detection predicts tumors a year before they form: breakthrough
March 27, 2023 | msn.com
Genetic testing: How four generations of a family have battled multiple cancers
March 25, 2023 | msn.com
Saliva: The Next Frontier In Cancer Detection
March 25, 2023 | news.yahoo.com
Hundreds call helpline over Orkney cancer gene
March 23, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on Cancer Genetics (NASDAQ:CGIX)
March 13, 2023 | msn.com
San Diego Genetic Sequencing Pioneer Illumina Fends Off Carl Icahn Proxy Bid
March 5, 2023 | benzinga.com
PROSTATE CANCER FOUNDATION-FUNDED GENETIC STUDY OF MEN OF AFRICAN ANCESTRY FINDS NEW RISK FACTORS FOR PROSTATE CANCER
See More Headlines

CGIX Price History

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CGIX
CUSIP
N/A
CIK
N/A
Web
www.cancergenetics.com
Phone
(201) 479-1357
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$6.33 million
Price / Sales
0.13
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,085,000
Free Float
N/A
Market Cap
$831,297.50
Optionable
Not Optionable
Beta
2.72

Key Executives

  • John A. Roberts
    President, Chief Executive Officer & Director
  • Andrew D. C. LaFrence
    Chief Operating & Financial Officer
  • Robert T. Fremeau
    Chief Scientific Officer
  • Ping Yeh
    Director & Chief Innovation Officer
  • Ralf Brandt
    President-Discovery & Early Development Services

Key Competitors

View All Competitors













CGIX Stock - Frequently Asked Questions

How have CGIX shares performed in 2023?

Cancer Genetics' stock was trading at $0.7025 on January 1st, 2023. Since then, CGIX shares have decreased by 71.0% and is now trading at $0.2035.
View the best growth stocks for 2023 here.

What is Panna Sharma's approval rating as Cancer Genetics' CEO?

28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com. Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cancer Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cancer Genetics investors own include Actinium Pharmaceuticals (ATNM), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Activision Blizzard (ATVI), Ford Motor (F), Gilead Sciences (GILD), CymaBay Therapeutics (CBAY), Synergy Pharmaceuticals (SGYP) and TherapeuticsMD (TXMD).

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How do I buy shares of Cancer Genetics?

Shares of CGIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cancer Genetics' stock price today?

One share of CGIX stock can currently be purchased for approximately $0.20.

How much money does Cancer Genetics make?

Cancer Genetics (NASDAQ:CGIX) has a market capitalization of $831,297.50 and generates $6.33 million in revenue each year.

How can I contact Cancer Genetics?

Cancer Genetics' mailing address is 201 State Rt 17 Fl 2, Rutherford, New Jersey 07070-2597. The official website for the company is www.cancergenetics.com. The company can be reached via phone at (201) 479-1357.

This page (NASDAQ:CGIX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -